We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+13.9%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$312M
AUM Growth
+$49M
Cap. Flow
+$16M
Cap. Flow %
5.14%
Top 10 Hldgs %
48.72%
Holding
62
New
16
Increased
14
Reduced
12
Closed
19

Top Buys

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$10.5M
2
PAY
Verifone Systems Inc
PAY
+$10.2M
3
HAIN icon
Hain Celestial
HAIN
+$8.59M
4
PDLI
PDL BioPharma, Inc.
PDLI
+$8.35M
5
ACOR
Acorda Therapeutics
ACOR
+$7.86M

Top Sells

Rank Stock Value
1
SGI
Somnigroup International
SGI
+$7.97M
2
TLRD
Tailored Brands, Inc.
TLRD
+$6.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$6.59M
4
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$6.26M
5
SNY icon
Sanofi
SNY
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 42.01%
2 Miscellaneous 21.04%
3 Consumer Discretionary 17.85%
4 Consumer Staples 13.73%
5 Technology 4.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$815B
$51.9M 16.66%
240,000
+60,000
+33% +$13M
ATRS
2
DELISTED
Antares Pharma, Inc.
ATRS
$20.7M 6.63%
12,300,000
-3,130,000
-20% -$3.83M
HAIN icon
3
Hain Celestial
HAIN
$67.5M
$12.4M 3.97%
348,000
+196,000
+129% +$8.59M
ACOR
4
DELISTED
Acorda Therapeutics
ACOR
$11.4M 3.67%
4,567
+2,634
+136% +$7.86M
ARLZ
5
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$10.2M 3.27%
2,100,000
-564,000
-21% -$2.57M
RXDX
6
DELISTED
Ignyta, Inc.
RXDX
$9.21M 2.96%
1,464,000
-92,000
-6% -$534K
PCRX icon
7
Pacira BioSciences
PCRX
$1.05B
$9.17M 2.94%
+268,000
New +$10.5M
VNDA icon
8
Vanda Pharmaceuticals
VNDA
$328M
$9.15M 2.94%
550,000
-250,000
-31% -$3.37M
PAY
9
DELISTED
Verifone Systems Inc
PAY
$8.88M 2.85%
+564,000
New +$10.2M
BHC icon
10
CALL
Bausch Health
BHC
$2.45B
$8.84M 2.84%
360,000
+120,000
+50% +$3.11M
PDLI
11
DELISTED
PDL BioPharma, Inc.
PDLI
$8.82M 2.83%
+2,632,000
New +$8.35M
LVS icon
12
Las Vegas Sands
LVS
$28.7B
$8.17M 2.62%
142,000
-22,000
-13% -$1.13M
FRPT icon
13
Freshpet
FRPT
$3.38B
$7.99M 2.56%
924,000
+174,000
+23% +$1.71M
NOMD icon
14
Nomad Foods
NOMD
$1.63B
$7.57M 2.43%
640,000
-160,000
-20% -$1.61M
AVDL
15
DELISTED
Avadel Pharmaceuticals
AVDL
$7.44M 2.39%
600,000
+251,997
+72% +$3.29M
DECK icon
16
Deckers Outdoor
DECK
$11.7B
$7.15M 2.29%
720,000
+120,000
+20% +$1.26M
PRKS icon
17
United Parks & Resorts
PRKS
$1.83B
$7.12M 2.28%
+528,000
New +$7.23M
KATE
18
DELISTED
Kate Spade & Company
KATE
$6.85M 2.2%
400,000
+142,000
+55% +$2.75M
SGYP
19
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$6.83M 2.19%
1,240,000
-90,000
-7% -$421K
THC icon
20
Tenet Healthcare
THC
$21.3B
$5.98M 1.92%
264,000
+36,000
+16% +$937K
WFM
21
DELISTED
Whole Foods Market Inc
WFM
$5.67M 1.82%
+200,000
New +$6.16M
ENTA icon
22
Enanta Pharmaceuticals
ENTA
$410M
$5.64M 1.81%
212,000
-28,000
-12% -$650K
BWLD
23
DELISTED
Buffalo Wild Wings, Inc.
BWLD
$5.63M 1.81%
40,000
-16,000
-29% -$2.49M
MNRO icon
24
Monro
MNRO
$415M
$5.26M 1.69%
+86,000
New +$5.22M
BBY icon
25
Best Buy
BBY
$19B
$5.19M 1.67%
+136,000
New +$4.77M
1
2 3

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Armistice Capital held 62 positions worth $312M, up 19% from $263M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Armistice Capital deployed $16M of net new capital in Q3 2016, opening 16 new positions and adding to 14 existing holdings. Its largest new stake was Pacira BioSciences: 268,000 shares worth $9.17M.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 40% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was Tailored Brands, Inc., an estimated $6.9M trimmed.

  • Armistice Capital's largest Q3 2016 buy was Pacira BioSciences: 268,000 shares worth $9.17M.
  • Armistice Capital added most to Hain Celestial in Q3 2016, an estimated $8.59M increase.
  • Armistice Capital's biggest Q3 2016 reduction was Tailored Brands, Inc., cutting an estimated $6.9M.
  • Armistice Capital fully exited Somnigroup International in Q3 2016, selling an estimated $7.97M.
  • Armistice Capital's ten largest holdings make up 49% of its $312M portfolio in Q3 2016.
  • Armistice Capital opened 16 new positions and closed 19 in Q3 2016.
  • Armistice Capital's portfolio value rose 19% quarter-over-quarter to $312M.

Based on Armistice Capital's 13F filing for Q3 2016, filed 14 Nov 2016.